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Accurate estimates of breast and ovarian cancer penetrance in BRCA1/2 mutation carriers are crucial in
genetic counseling. Estimation is difficult because of the low frequency of mutated alleles and the often-
uncertain mechanisms of family ascertainment. We estimated the penetrances of breast and ovarian
cancers in carriers of BRCA1/2 mutations by maximizing the retrospective likelihood of the genetic model,
given the observed test results, in 568 Italian families screened for germline mutations. The software
BRCAPRO was used as a probability calculation tool in a Markov Chain Monte Carlo approach. Breast
cancer penetrances were 27% (95% CI 20–34%) at age 50 years and 39% (27–52%) at age 70 in BRCA1
carriers, and 26% (0.18–0.34%) at age 50 and 44% (29–58%) at age 70 in BRCA2 carriers, and ovarian
cancer penetrances were 14% (7–22%) at age 50 and 43% (21–66%) at age 70 in BRCA1 carriers and 3%
(0–7%) at age 50 and 15% (4–26%) at age 70 in BRCA2 carriers. The new model gave a better fit than the
current default in BRCAPRO, the likelihood being 70 log units greater; in addition, the observed numbers
of mutations in families stratified by gene and by cancer profile were not significantly different from those
expected. Our new penetrance functions are appropriate for predicting breast cancer risk, and for
determining the probability of carrying BRCA1/2 mutations, in people who are presently referred to
genetic counseling in Italy. Our approach could lead to country-customized versions of the BRCAPRO
software by providing appropriate population-specific estimates.
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Introduction
Mutations in the two genes BRCA1 (MIM 113705) and
BRCA2 (MIM 600185) account for 30–40% of the families
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families with multiple breast and ovarian cancers cases.1–3
Taken together, these genes may be responsible for 5–10% of
early-onset breast cancers4–7 and about 10% of all ovarian
cancers.8 Estimates of cancer risks among mutation carriers
provide valuable opportunities to tailor cancer screening and
prevention strategies and to refine clinical and behavioral
interventions to reduce cancer risk.9–12
Initial studies of multiple-case families with four or more
cancer cases suggested that the lifetime risk of breast cancer
in BRCA1 mutation carriers was 71–85%, and that of
ovarian cancer was 42–63% at age 70.13,14 Similarly, early-
penetrance evaluations in BRCA2 led to an 84% risk of
breast cancer and 27% for ovarian cancer at age 70.2 Later
studies, based on extensive typing of incident cases, have
provided lower risks,15 – 17 for example, 40% penetrance of
breast cancer at age 7015 or 48% at age 80,17 though with
large sampling errors. A recent combined analysis of several
previous studies18 estimated the risk of breast cancer to be
about 64% in BRCA1 and 39% in BRCA2 mutation carriers
at age 70. Substantial uncertainty in the estimates remains.
Issues of variation across different populations and across
different mutations of the same gene need to be investi-
gated in further detail.19
In the present work, we have addressed the question of
estimating cancer- and gene-specific penetrances appro-
priate for the mutations segregating in a large sample of
Italian multiple-case families screened for both genes. We
used the software BRCAPRO,20,21 a widely used program for
predicting the presence of a germline mutation in a
proband. Since the prediction made by this program is
based on a specific genetic model (the set of parameter
values, allele frequencies and penetrances that define the
risk of disease in the population), it is possible to reverse
the approach, that is, estimating some of the parameters
from family data. This is accomplished by iteratively
exploring new parameter values until the best genetic
model is found, for which the prediction made by
BRCAPRO is more accurate. In this approach, the like-
lihood of the genetic data (the observed test results)
conditional on the phenotype is calculated. This is called
the retrospective likelihood, and parameter estimates based
on it remain unbiased even when the ascertainment
method cannot be specified accurately, provided that
ascertainment depends on phenotypes only.22 While use
of the retrospective likelihood has precedents,2 our
approach is novel in that it includes families negative at
the genetic test, and accounts for test sensitivity.
Materials and methods
The families included in the present study have been
described previously.23 Briefly, 568 Caucasian families
ascertained in five clinical centers were submitted to
genetic test for BRCA1 and/or BRCA2 (458 families were
screened for both BRCA1 and BRCA2, 104 for BRCA1 only
and eight for BRCA2 only). Among the families included in
this study, 151 presented both breast and ovarian cancer,
either in a single individual or in different relatives
(hereditary breast-ovarian cancer (HBOC)), 357 included
patients with breast cancer only (hereditary breast cancer
(HBC)), 31 included patients with ovarian cancer only
(hereditary ovarian cancer (HOC)), and 29 included at least
one case of male breast cancer (MBC). In the present study,
we estimate penetrance functions for females only, as the
number of males affected with breast cancer is too small.
Eligibility criteria for genetic testing varied across centers
and, within centers, over time; families with multiple cases
of breast/ovarian cancer or early-onset cancer cases were
preferentially selected. Pedigree data were reported by
family members to genetic counselors, and included
information about breast and ovarian cancer in first- and
second-degree relatives of probands. In total, 85 distinct
germ-line mutations (46 in BRCA1 and 39 in BRCA2) were
detected in 133 independently ascertained probands (26%
of the screened families, 80 with mutation in BRCA1 and
53 in BRCA2, see Figure 1); 15 mutations of BRCA1 and
seven mutations of BRCA2 were identified more than once,
with a maximum of nine families with BRCA1*5382insC
and four families with BRCA2*6696delTC and
BRCA2*IVS16-2A4G. These mutation frequency spectra
are typical of large, non-isolated populations. In mutation
analysis, three centers used both direct automatic sequen-
cing and PTT-SSCP, one center used both PTT-SSCP and
fluorescence-assisted mutational analysis (FAMA) and the
last center used PTT-SSCP only.
The program BRCAPRO computes the probability that a
proband is a carrier of a mutation in either BRCA1 or
BRCA2, based on the family history of breast and ovarian
cancer in her first- and second-degree relatives and on
published estimates of cancer-specific penetrances and
mutated-allele population frequencies; model parameter
files are regularly updated following published studies.21,24
BRCAPRO is also distributed as a part of the counseling
package CaGene.25 In the present context, BRCAPRO is
used as a probability calculation tool to obtain new
parameter estimates via a Metropolis–Hastings26 Markov-
Chain Monte Carlo (MCMC) method.27
The equations used to model the penetrance functions
have the following form:
fg;jðxÞ ¼ f0;jðxÞYðxÞ ð1Þ
where fg,j(x) is the incidence at age x for the carriers of a
mutation in gene g (g¼1 or 2 for BRCA1 and BRCA2,
respectively) for cancer type j (j¼1 or 2 for breast and
ovarian cancer, respectively), f0,j(x) are the corresponding
incidences among non-carriers, and Y(x)¼ W0þ W1xþ W2x2.
Coefficients W0, W1, and W2 are estimated. This form of the
penetrance function allows for a parsimonious representa-
tion of the relationship between cancer, genotype and age.
The density of cases in the general population, estimated
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using cancer registry data,21 is used as a baseline. The
parameter W0 allows for an increase in risk across all ages,
while the parameters W1 and W2 allow to flexibly incorpo-
rate effects of genotype on age of onset. We also constrain
the term Y(x) so that it is always greater than 0, to avoid the
possibility of a lower penetrance in mutation carriers than
in noncarriers. In addition to the penetrance functions, we
also estimate from data the proportion m¼ p1/(p1þ p2),
where p1 and p2 are the population frequencies of the
mutated alleles in BRCA1 and BRCA2, respectively; total
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Figure 1 BRCA1 and BRCA2 maps of the mutations included in the present study, with indication of the number of families in
which each mutation was identified.
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prevalence of mutation carriers is thus approximately
2(p1þ p2). We assume uniform prior distributions on all
parameters.
At the kth iteration of the MCMC algorithm, a new set of
parameters Ws and m is formed, based on the parameter
values at the (k1)th iteration and a proposal drawn from a
multivariate t distribution, and the corresponding pene-
trance functions are calculated; the carrier probabilities are
then determined by BRCAPRO for all the families in the
study, and the total log likelihood of the new parameter
set, given the observed test results, is calculated as
log L ¼
X
ifz10i log ½bp10i þ bð1  bÞp11i 
þ z01i log ½bp01i þ bð1  bÞp11i 
þ z11i log ðb2p11i Þ
þz00i log ½p00i þ ð1  bÞp10i þ ð1  bÞp01i þð1bÞ2p11i g
where the zi’s are indicator variables pointing to the carrier
status of proband i (10¼BRCA1, 01¼BRCA2, 00¼no
mutation, 11¼mutation in both genes), the pi’s are the
corresponding carrier probabilities, and b is the sensitivity
of the genetic test, set to 0.7.21 In the families screened for
one gene only, the log-likelihood function is modified by
assuming that the determination of which gene to test is
independent of genotype, as follows:
log L ¼
X
i fz1i log ½bp1i  þ z0i log ½ð1  bÞ 
 p1i þ p0i g:
The proposed parameter set at each iteration k is accepted
with probability¼1 if Lk4Lk1 and with probability¼
Lk/Lk1 otherwise. Confidence intervals of parameters are
obtained by examining their variation among the last 5000
iterations (after parameter values are stabilized); for each
year of age, the values that excluded the 2.5% upper and
lower tails of the penetrance distribution are taken as the
95% confidence intervals.
In our retrospective likelihood approach, it is not
possible to estimate allele frequencies for the two genes
separately along with penetrance parameters Ws; therefore,
the sum p¼ p1þ p2 was initially set to 0.003.2,14,28,29 Gene-
specific allele frequencies are not being estimated in this
work, only their ratio. The entire analysis was also repeated
considering the P-values 0.001, 0.002, 0.004 and 0.005. We
first considered the full ‘quadratic’ model including three
parameters for each of four penetrance functions plus the
proportion m of BRCA1 vs BRCA2 mutation in the
population (total parameters 13). To check if the model
could be simplified without affecting the overall fit, we also
used the ‘linear’ function Y(x)¼ W0þ W1x in equation (1);
this led to a reduction in the number of estimated
parameters from 13 to 9.
Results
In all calculations, the sample stabilized in less than 2000
iterations, though the chains were continued for 10 000
iterations. Acceptance rate was near 40%. Considering the
model with P fixed to 0.003, we obtained a final log
likelihood, evaluated at point estimates, of about 326 for
both the quadratic and the linear models, and the four
resulting penetrance curves were practically indistinguish-
able. Therefore, we accepted the linear model. Repeating
the analysis with lower values of P (0.001 and 0.002) had
the effect of decreasing the equilibrium values of the log
likelihood to about 345 and 331, respectively (19 and 5
log unit difference). On the other hand, increasing P to
0.004 and 0.005 caused a slight increase in log likelihood
(324 and 322, respectively); however, the penetrance
curves associated to these values were still lower. For
example, breast cancer risk for BRCA1 carriers at age 70
decreased from 39% (P¼ 0.003, see Table 1) to 35%
(P¼0.004) to 34% (P¼ 0.005).
The four new penetrance curves of breast and ovarian
cancer in BRCA1-2 mutation carriers corresponding to the
model with p¼0.003 are shown in Figure 2, together with
95% confidence limits. Dotted lines show, as a reference,
the default penetrance curves distributed with BRCAPRO,
used in our previous study.23 Breast cancer penetrance is
lower, especially for BRCA1 carriers, whereas ovarian
cancer penetrance in BRCA1 is higher (though the
reference ovarian cancer penetrance curve is included in
the 95% confidence limits of our estimate). The penetrance
of ovarian cancer in BRCA2 is similar to the reference.
Table 1 compares cancer penetrances at 50 and 70 years of
age, as estimated by our model, to those of previous
studies, whereas Table 2 shows the age-specific incidences
at 10-year intervals in our estimates. Considering the
frequency of the mutated alleles, the value of the
parameter m was 0.57 (95% CI 0.44–0.69), leading to an
estimate of 3.4103 for the prevalence of BRCA1
mutation carriers (B1:300 individuals) and 2.6103 for
that of BRCA2 mutation carriers (B1:400 individuals) in
our sample.
Lastly, we used the estimated penetrances as input in
BRCAPRO to predict the presence of a mutation in
probands in our sample. As those are the same samples
used in training the model, this exercise is a goodness-of-fit
evaluation rather than a validation. In our previous
evaluation study,23 it emerged that none of the currently
available mutation-predicting models was able to accu-
rately discriminate between the two genes, either because
models did not address this (eg, Myriad Tables and Couch
model) or because the discriminating ability was limited
(BRCAPRO and IC models). However, difference in ex-
pressivity may be better exploited to distinguish between
the two genes.30 We investigated this issue by stratifying
our families in the four typical profiles (HBC, HBOC, HOC,
and MBC), and computing the observed and expected
number of mutations separately for the two genes (Table 3).
While the estimated parameter values maximize the overall
fit by construction, it is interesting to explore whether the
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fit varies by subgroup. We assessed calibration (the
correspondence between observed and expected number
of cases) by applying the w2 test. The observed numbers of
mutations in the four family profiles were not significantly
different from those expected, both considering total data
and data separated by gene. The highest w2 contributions
come from MBC families (penetrance of MBC was not
estimated in the present work). The last column in Table 3
shows the difference between the log likelihoods computed
with the penetrance functions estimated in this work and
the default penetrance functions in BRCAPRO; the highest
increases concern the HBC families in BRCA2 and the
HBOC families in BRCA1. HBC families were disproportio-
nately assigned to BRCA1 by the previous predictions.
Discussion
Determining the appropriate values of cancer risks in
women who carry a mutation in BRCA1 or BRCA2 is crucial
for establishing the most appropriate preventive measures.
However, estimation of penetrance is a difficult task, being
subjected to different sources of bias;31 considerable
uncertainties remain about the ‘true’ values. A novel aspect
of the present work is that it includes information from all
tested families, both mutation-positive and mutation-
negative; previously published estimates were based on
information drawn from pedigrees of mutation carriers
only.2,16 – 18 Our approach consisted in determining the
penetrance curves that optimize the goodness-of-fit of a
Mendelian model that predicts the presence of a mutation
in a proband, given its personal and family cancer history.
An advantage of this methodology is that it can be applied
to family collections whose ascertainment scheme is loose.
The most noticeable result of this work is that the breast
cancer penetrance in BRCA1 carriers is lower than in
previous studies. An important feature of our family data
set is the high proportion of families with mild family
history, which probably reflects the recent increase of
genetic-test demand. From this point of view, our study
sample may be considered intermediate between the
multiple-case studies, based on highly selected families,
and the population-based studies, in which typing is
performed irrespective of family history of cancer; our
penetrance estimates are more consistent with the latter
studies. We have previously shown23 that all extant
predictive models underestimated the probability of iden-
tifying mutations in the families with calculated prior
probability o10%. If a persistent excess of mutations is
identified as far as more and more low-risk families are
typed, this supports the idea that cancer penetrances of
these mutations were previously considered too high.
A complication in estimating a certain penetrance curve
is that a single entity common to all populations may not
exist;32 each population has its own mutation spectrum,T
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with different prevalence of specific founder mutations,
and different mutations may confer different breast and
ovarian cancer risk. Consequently, each study estimates
the average risk to carriers specifically for the population
being studied. The population included in the present
study is representative of the patient population that is
referred for genetic testing for BRCA1 or BRCA2 mutations
in Italy. Genetic counselors are interested in penetrance
estimates relevant to the risks in the sort of families that are
coming into counseling; thus, our estimated model is
appropriate for use in determining the probability of
carrying BRCA1/2 mutations in Italian families. We are
implementing a version of BRCAPRO that can be distrib-
uted to genetic clinics in this country.
Another explanation for the finding of lower breast
cancer risk accompanied by increased ovarian cancer risk
in BRCA1 carriers could be the presence of a particular
mutation spectrum in the study set, for example, if there
was an unusually high proportion of mutations associated
with early-onset ovarian cancer; however, this is not the
case, as it was shown in our previous analysis of a similar
data set,30 and it is also apparent by inspection of Figure 1.
However, this issue should be investigated in greater
details, as there may be substantial allelic heterogeneity
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Figure 2 Breast and ovarian cancer penetrances in BRCA1 and BRCA2 mutation carriers estimated in the present work, with
95% confidence limits (dark and light continuous lines, respectively). Dotted lines: default penetrance functions in BRCAPRO.
Table 2 Age-specific incidences (with 95% CI) of breast and ovarian cancer in BRCA1-2 mutation carriers
BRCA1 BRCA2
Age Breast cancer Ovarian cancer Breast cancer Ovarian cancer
20–29 0.025 (0.016–0.034) 0.018 (0.004–0.033) 0.018 (0.009–0.028) 0.003 (0.000–0.008)
30–39 0.100 (0.073–0.126) 0.036 (0.014–0.057) 0.087 (0.057–0.118) 0.008 (0.000–0.016)
40–49 0.134 (0.100–0.167) 0.078 (0.042–0.114) 0.143 (0.109–0.178) 0.021 (0.006–0.036)
50–59 0.085 (0.053–0.116) 0.131 (0.072–0.189) 0.112 (0.079–0.145) 0.044 (0.018–0.071)
60–69 0.048 (0.023–0.073) 0.171 (0.075–0.267) 0.076 (0.040–0.113) 0.076 (0.022–0.131)
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in cancer risks in both BRCA1 and BRCA2.16,17,33 This issue
has received little attention until recently, as it requires
collecting large samples of families sharing the same
mutations. We are investigating this issue in our data. It
is possible that at least some of the mutations identified in
families at relatively low cancer risk contribute to lower the
average penetrance in comparison with the previous
estimates, which were necessarily based on highly selected
families, that is, those possibly harboring mutations with a
relatively stronger phenotypic effect.
A disadvantage of the approach used here is that it is not
possible to estimate simultaneously both the mutated
allele frequencies and the penetrances in the same data
set. Even in previous studies, either the prevalence of gene
carriers assuming known penetrances were estimated,4,17
or the penetrances assuming known prevalence were
estimated.2,13 We have chosen an initial value of 0.003
for the cumulative frequency of the mutated alleles based
on an early segregation analysis study,28 in which all the
parameters of the genetic model (gene frequency and
penetrances) can be independently estimated; this re-
quires, however, that the ascertainment method is clearly
defined. We have tried to address the robustness of our
penetrance estimates by repeating the entire analysis with
different values of the cumulative allele frequency. Values
lower than 0.003 caused a decrease in the total log
likelihood, whereas higher values caused a small increase
in the log likelihood, accompanied by a further decline of
the penetrances. Therefore, the genetic model with
p¼0.003 may represent a combination of values (allele
frequencies and penetrances) that gives a good representa-
tion of reality, though for an ultimate answer we probably
must wait until technology will allow estimating the allele
frequencies by direct allele count in large random samples
of the general population.
A key element of the genetic counseling consultation is
the identification of probands whose risk is higher than a
certain threshold, such as to justify the genetic test. The
ASCO has recently suggested that BRCA gene mutation
screening should be limited to individuals whose prob-
ability for carrying a mutation is at least 10%.25,34 Applying
this criterion to our new model, we find 338 probands with
carrier probability 410% (59.5% of all families), among
which 119 mutations in either gene were identified, or a
mutation detection rate of 35.2%. On the other hand, 14
mutations (seven in each gene) have been identified in the
230 probands (40.5%) with probability o10%, or a
mutation detection rate of 6.1%. Considering the default
penetrance files distributed with BRCAPRO, 263 families
(46.3% of total sample) had carrier probability 410%, in
which 101 mutations were detected (whereas 32 mutations
were found in the low-risk group). Therefore, the 10%
probability threshold requires testing 75 more families in
the new model (an increase of 13.2%), but the proportion
of mutations identified in the low risk group is lowered
from 24.1 to 10.5%. Thus, not only the old model classified
a higher number of families at low risk, but also the
proportion of mutations identified among them was
higher.
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